Emerging Practice Points from the UPC

No items found.
​
September 2, 2025

Jurisdiction

Recent cases have shown that the UPC has a broad jurisdiction, perhaps wider than many had expected, both in terms of geographical and temporal reach.

The UPC has jurisdiction beyond the signatory states.

The UPC has jurisdiction to hear patent infringement claims in respect of all national designations of EP patents, including in respect of non-UPC states and even non-EU states, where at least one defendant is domiciled in a UPC state.

This approach was first set out in the decision of the Dusseldorf Local Division in Fujifilm v Kodak but has gained real traction following the decision from the CJEU in BSH v Electrolux[1]. In the Electrolux case, in a significant shift from the CJEU's previous decision in GAT v LuK[2], the CJEU held that a national court in which a defendant is domiciled has jurisdiction to determine an allegation of patent infringement where the patent was granted by another EU state and even where validity is contested.

This significant shift has been seized upon by many claimants before the UPC resulting in a string of decisions showing how the decision will be applied by the UPC: As the UPC is deemed to be a court of a Member State[3], so long as the proceedings are brought in the local division in which one of the defendants to an action is domiciled, that court will have jurisdiction to adjudicate on infringement issues related to European patents validated in non-UPC Countries.[4] This approach was followed by the Court of Appeal of the UPC in TGI Sport Suomi Oy and others v AIM Sport Development AG. In that case AIM had brought infringement proceedings in the Helsinki Local Division against a TGI Sport Suomi Oy, a company domiciled in Finland. AIM were granted leave to amend their case (amongst other things) to add a UK group company as a Defendant in relation to alleged infringing activities in Germany and Spain, jointly with other defendants. TGI's appeal against that decision was unsuccessful.

The UPC has now issued a partial injunction for one amended[5] patent covering the UK, as well a separate finding of invalidity for a different patent, on an inter partes basis only; see Fujifilm v Kodak.

The UPC has jurisdiction to deal with acts pre-dating its formation

Earlier this year, the case of Esko-Graphics Imaging GmbH v XSYS Germany GmbH highlighted that the UPC's jurisdiction extends both to:

  1. acts of use done by a defendant prior to 1 June 2023 (the entry into force of the UPCA), and
  2. acts which took place during a period when a patent was opted out of the of the UPC's exclusive jurisdiction where that opt-out is subsequently withdrawn.

Service on foreign defendants

Service on foreign defendants may prove slower than hoped by Claimants, as the Court of Appeal of the UPC has confirmed in Panasonic v Xiaomi that service on foreign defendants must follow the procedures prescribed by the Hague Service Convention, and that only once service under the Hague Service Convention has been attempted will the court considered authorising alternative service[6]. Experience suggests that this is likely to cause delays in serving Chinese defendants in particular, where service under the Hague convention is often slow due to additional requirements imposed on parties by the Chinese and Hong Kong Central Authorities.

The Panasonic decision does provide some comfort for prospective claimants, as in that case the court split the claim against the Hong Kong entity and other Chinese entities from the original infringement action and allowed the original infringement action to continue and made an order for alternative service on the defendants in Hong Kong and China, ordering that the steps already taken constituted valid service. Such decisions on alternative service are however fact specific.

Extensions of time are rarely granted

Whilst some extensions were granted while systems were bedding in during the early months of the UPC, such as in Edwards Lifesciences v Meril[7], more recent decisions indicate that the UPC will only grant extensions of time in exceptional circumstances. Even when extensions are granted, any extensions are generally short.

Generally, successful applications will require evidence of the objective need for the extension and parties are obliged to submit a request for an extension as soon as it appears clear that it will not be possible to meet a deadline. In ITCiCo Spain SL v BMW AG the Paris Central Division refused an application for an extension to file a defence to a revocation action made the day before the deadline. The court found that the issues relied on by the applicant should have been apparent much earlier. The court's Order states that parties are ‘expected to seek a solution in an appropriate time and act accordingly'. Failure to make an adequately evidenced application in good time can have serious consequences and in that case the defendant's patent was revoked by default.

Amendments should be made promptly

Should amendments to pleadings be necessary, parties are advised to make the application as soon as the change of circumstances or knowledge of new facts necessitates the amendments.

Esko-Graphics Imaging GmbH were refused permission to include a claim for infringement in the Netherlands having made such application 10 weeks after learning of the reinstatement of its patent in the Netherlands, even though the court was satisfied that the amendment would not unreasonably hinder the other party in the conduct of the action. The court found that in line with standard of diligence required, it should only have taken 4 weeks to get advice and to decide whether make amendments and therefore refused permission to make the amendment, as it could have been made earlier with reasonable diligence at an earlier stage.

Security for costs

The court has discretion to grant an order for security if the financial position of the other party gives rise to a legitimate and real concern that costs may not be recoverable or that a costs order may not be enforceable, or will only be so in an unduly burdensome way.[8]

The burden of proof lies with the applicant[9]. Once an applicant has presented credible reasons and facts it is for the opposing party "to challenge these reasons and facts in a substantiated manner, especially since that party will normally have knowledge and evidence of its financial situation. It is for the Claimant to argue that and why a security order would unduly interfere with [their rights]": see Maxeon v Aiko.

It was thought that applications could be brought by any party as Rule 158 of the UPC Rules of Procedure provides that the court may order security for costs "following a reasoned request by one party"[10].However, following the more recent Court of Appeal decisions in Aortic Labs Srl v Emboline Inc it is now understood that Article 69(4) of the UPCA imposes a limit on this broad rule and only defendants may be allowed to make applications for security for costs. Further, in cases where both parties are claimants and defendants for different parts of the case (e.g. where there has been a counterclaim for revocation), only the defendant in the initial claim can make an application for costs.

Independence of representatives – the rights of in-house counsel are limited

Each party requires a named representative, and this representative is required to be an independent third person. Whilst the Court of Appeal of the UPC held in Suinno v Microsoft[11] that this can be someone employed by a party, in many cases this might not be possible due to the requirements for independence and not someone with "extensive administrative and financial powers within the legal person".

Specifically, in Suinno the Court of Appeal stated that a person with such powers, "whether as a result of holding a high-level management or administrative position or holding a significant amount of shares in the legal person", would not be able to act as the "independent counsellor by serving the interests of his or her client in an unbiased manner without regard to his or her personal feelings or interests".

This article was last updated on 4 August 2025.

[1] CURIA - BSH Hausgeräte GmbH v Electrolux AB

[2] CURIA - GAT v LuK

[3] Article 71a of the Recast Brussels Regulation.

[4], Alpinestars SPA v Dainese SPA. See also Mul-T Lock France v IMC, Creations, Synegenta v Sumi Agro, and Seoul Viosys v Laser Components.

[5] The amendments had not been requested at the UKIPO at the time of the decision. The amendments are therefore only effective inter partes.

[6] Panasonic Holdings Corporation v Xiaomi H.K. Limited (UPC_CFI_330/2024, UPC_CFI_332/2024 and UPC_CFI_335/2024)

[7] UPC Exceptionally grants extension of time limit for preliminary objection; Extension of time limit for statement of defence

[8] Article 69(4) UPCA and Rule 158 RoP

[9] AYLO PREMIUM LTD v DISH Technologies L.L.C.

[10] See for example Aylo v Dish

[11] ORDER_Suinno v Microsoft_2025_02_11, see paragraph 23

The Latest Thought Leadership pieces in the Content Hub

UPC Considers but does not decide exhaustion of rights in relation to consumables
October 30, 2025
Brita v. Aquashield UPC CFI 248/2024 (Munich LD), decision of 22 August 2025[1] UPC CFI 564/2024 (Munich LD), decision of 16 October 2025[2] Brita sued Aquashield and others for infringement of...
UPC takes strict approach on costs reimbursement
October 30, 2025
Insulet v. EOFlow UPC_CFI_773/2025 and UPC_CFI 774/2025 (Milan CD), decision of 15 October 2025[1] The dispute began when Insulet sought a provisional injunction against EOFlow to prevent...
UPC Agreement Is Not EU Law, No Referrals to CJEU
September 1, 2025
expert v. Seoul Viosys, UPC_CoA_380/2025 Order of 20 August 2025 (ORD_22147/2025)[1] This order from the UPC Court of Appeal clearly states that the Court of Justice of the EU cannot be asked to...
Unconventional Service: igus v. Whale Technology
August 29, 2025
UPC_CFI_318/2025, decision of 5 August 2025 (ORD_34299/2025)[1] In a default judgment issued by the Düsseldorf Local Division of the Unified Patent Court, Whale Technology (Shanghai) Co., Ltd.
Stay in the Know

The Patent Strategist

Get expert insights and the top patent stories delivered straight to your inbox.

Heading
This is some text inside of a div block.
This is some text inside of a div block.

Latest Insights

Showing 0 of 100
Is Your AI Conversation Privileged?
08 May 2026
Recent US court decisions have, for the first time, tested whether conversations with AI tools can be protected by legal privilege. In United States v. Heppner, a court held that documents generated by a defendant using a public AI platform were not protected by attorney‑client privilege, largely because the AI was not used within a lawyer‑directed relationship and the platform’s terms allowed data retention and disclosure. By contrast, in Warner v. Gilbarco, another court found that AI‑assisted materials created by a self‑represented litigant were protected under the work‑product doctrine, which has a more forgiving standard for waiver.
#
Consulting
​
The evolution of nucleic acid sequencing and what it means for Genomics and IP
27 April 2026
This article outlines the evolution of nucleic acid sequencing, from early Sanger methods to next‑generation and long‑read technologies. The journey from deciphering individual DNA strands to sequencing entire genomes in hours represents one of biotechnology's most impressive transformations. The first human genome, completed through the Human Genome Project, took around 13 years to sequence and cost billions of dollars, whereas modern sequencing methods can now deliver a genome in hours for a few hundred dollars. For those interested in patents and life sciences, understanding the technical evolution of sequencing methods offers insights into how fundamental scientific advances translate into valuable patent portfolios.
#
Consulting
​
World IP Day: The big ideas shaping IP's fastest-moving fields
24 April 2026
For World IP Day, we asked experts of EIP’s five growth areas: Uniphy, Ampliphy, Stratiphy, Codiphy and Quantiphy, to share a quick insight on innovation, IP trends, and what excites them about the future. Each responded to a single, focused question reflecting the role their team plays across EIP.
#
Consulting
​
Meet the EIP team heading to INTA 2026 in London
23 April 2026
INTA's Annual Meeting is coming to London. From 2–6 May 2026, the ExCeL will host more than 10,000 trade mark and IP professionals from over 100 jurisdictions — five days of sessions, side events, and the kind of corridor conversations that turn into lasting working relationships.
#
Litigation
​
Antibody Patent Protection in Europe and the US: Navigating EPO and USPTO Differences
16 April 2026
This article explores the complexities of patenting antibody therapies, focusing on the differing requirements and practices of the European Patent Office (EPO) and the United States Patent and Trademark Office (USPTO). It highlights how the scope of claims, inventiveness standards, and supporting data requirements vary between jurisdictions, and explains why a tailored IP strategy is essential for innovators especially SMEs seeking protection in both Europe and the US. The article also outlines how EIP’s transatlantic teams collaborate to optimise patent applications for success in these key markets.
#
Patenting
​
Why competitor patent monitoring is critical to your drug development strategy
15 April 2026
This article explains why competitor IP monitoring is a critical part of an effective drug development strategy. By tracking competitor patent activity, companies can assess freedom to operate, identify risks and opportunities early, and make informed decisions on patent filings, licensing, and investment readiness. Ongoing monitoring also supports FTO analysis, third‑party observations, oppositions, and litigation strategy, helping life sciences businesses protect value and reduce risk throughout development.
#
Consulting
​
Biopharma Strategy in 2026: Lessons from 2025 on AI, M&A and the UPC
13 April 2026
This article looks back on a selection of key trends in the (bio)pharma industry in 2025 and looks ahead to how these may continue to develop into 2026.
#
Consulting
​
Thinking about IP from day one: strategic considerations for deep tech startups
08 April 2026
For deep tech startups, intellectual property decisions often come too late or cost too much too soon. This article explores why IP strategy should be considered from day one, even if formal protection comes later. It outlines how founders can decide what to patent, when trade secrets may be more appropriate, and how detectability, enforceability and cost should shape early choices. With a focus on practicality and commercial alignment, it also looks at how newer, AI‑assisted approaches can help startups take a more cost‑effective and flexible approach to building meaningful IP protection.
#
Consulting
​
National offices report increases in national patent applications throughout Europe: Is the EPO no longer “killing” the national offices?
27 March 2026
National patent offices across Europe have reported a marked increase in patent filings in 2025, breaking with a long‑standing downward trend. Data from Germany, France, Italy, Sweden, Austria, Spain and Norway point to growing activity driven by digital technologies, electrification and increased university participation. At the same time, offices report a rise in self‑drafted and AI‑assisted applications, which may lower barriers to entry but also raise concerns about application quality and examination efficiency.
#
Patenting
​
Make your bio(pharma) IP investment ready
22 March 2026
This recap of our LinkedIn Live series focuses on helping (bio)pharma businesses make their IP investment‑ready. Across three sessions, experts will discuss building resilient IP portfolios, making strategic IP decisions ahead of funding rounds, and what the evolving 2026 (bio)pharma landscape means for long‑term IP strategy.
#
Patenting
​
Are professional guidelines making Patent Attorneys too cautious on AI?
19 February 2026
As AI use accelerates in patent practice, many European patent attorneys remain cautious due to professional AI guidelines from the epi. This article argues those guidelines are not a barrier, but a baseline for responsible use.
#
Patenting
​
Provisional Agreement Reached on the EU Pharma Package: Takeaways for Pharmaceutical Companies
17 February 2026
The EU’s new Pharma Package will overhaul regulatory exclusivity, orphan drug incentives, antimicrobial innovation, and generic entry pathways, reducing standard protection periods while introducing new rewards like transferable exclusivity vouchers.
#
Patenting
​
Beyond CRISPR: Precision to Platform
23 January 2026
Gene editing is entering a new phase, moving beyond CRISPR-Cas9’s breakthrough but costly, bespoke therapies toward more precise and scalable platforms. While CRISPR-based treatments like Casgevy have proven clinical success, they remain expensive and entangled in ongoing patent disputes over foundational IP. Next-generation tools such as base editing and prime editing avoid double-strand DNA breaks, enabling more accurate corrections and broader therapeutic potential. The field’s focus is now shifting to disease-agnostic platforms that can be adapted across many conditions, improving access and efficiency.
#
Patenting
​
Confidentiality at the UPC: What litigants need to know
21 January 2026
This article explains how the Unified Patent Court approaches confidentiality in litigation, outlining the procedures for restricting access to sensitive information, how confidentiality clubs are formed, and when hearings may be held in private. It highlights key case law shaping these rules, the balance between fair trial rights and protection of commercial data, and the penalties for breaches. Practical guidance is provided to help parties navigate applications, manage confidential documents, and understand what to expect throughout UPC proceedings.
#
Litigation
​
EPO fees are going up in April 2026: Plan ahead now
19 January 2026
The European Patent Office will introduce a fee increase of roughly 5% from 1 April 2026, affecting search, examination, designation and renewal fees. Filing, excess page, opposition and appeal fees remain unchanged. Some costs—such as renewal fees—can be paid up to three months early, allowing applicants to secure the current lower rates. EIP recommends reviewing your portfolio ahead of the deadline.
#
Patenting
​